These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 32994205)

  • 21. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
    Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteopontin drives KRAS-mutant lung adenocarcinoma.
    Giopanou I; Kanellakis NI; Giannou AD; Lilis I; Marazioti A; Spella M; Papaleonidopoulos V; Simoes DCM; Zazara DE; Agalioti T; Moschos C; Magkouta S; Kalomenidis I; Panoutsakopoulou V; Lamort AS; Stathopoulos GT; Psallidas I
    Carcinogenesis; 2020 Aug; 41(8):1134-1144. PubMed ID: 31740923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
    Ricciuti B; Leonardi GC; Metro G; Grignani F; Paglialunga L; Bellezza G; Baglivo S; Mencaroni C; Baldi A; Zicari D; Crinò L
    Expert Rev Respir Med; 2016; 10(1):53-68. PubMed ID: 26714748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis.
    Rangel DF; Dubeau L; Park R; Chan P; Ha DP; Pulido MA; Mullen DJ; Vorobyova I; Zhou B; Borok Z; Offringa IA; Lee AS
    Oncogene; 2021 May; 40(20):3624-3632. PubMed ID: 33931739
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.
    Liu J; Cho SN; Wu SP; Jin N; Moghaddam SJ; Gilbert JL; Wistuba I; DeMayo FJ
    Lung Cancer; 2017 Oct; 112():47-56. PubMed ID: 29191600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
    Wood K; Hensing T; Malik R; Salgia R
    JAMA Oncol; 2016 Jun; 2(6):805-12. PubMed ID: 27100819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ETS1 regulates Twist1 transcription in a Kras
    Millien G; Cao Y; O'Hara CJ; Tagne JB; Hinds A; Williams MC; Ramirez MI; Kathuria H
    Clin Exp Metastasis; 2018 Mar; 35(3):149-165. PubMed ID: 29909489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD44 promotes Kras-dependent lung adenocarcinoma.
    Zhao P; Damerow MS; Stern P; Liu AH; Sweet-Cordero A; Siziopikou K; Neilson JR; Sharp PA; Cheng C
    Oncogene; 2013 Oct; 32(43):5186-90. PubMed ID: 23208496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.
    Baumgart A; Mazur PK; Anton M; Rudelius M; Schwamborn K; Feuchtinger A; Behnke K; Walch A; Braren R; Peschel C; Duyster J; Siveke JT; Dechow T
    Oncogene; 2015 Jan; 34(5):578-88. PubMed ID: 24509876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer.
    Sunaga N; Imai H; Shimizu K; Shames DS; Kakegawa S; Girard L; Sato M; Kaira K; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Int J Cancer; 2012 Apr; 130(8):1733-44. PubMed ID: 21544811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo screening identifies GATAD2B as a metastasis driver in KRAS-driven lung cancer.
    Grzeskowiak CL; Kundu ST; Mo X; Ivanov AA; Zagorodna O; Lu H; Chapple RH; Tsang YH; Moreno D; Mosqueda M; Eterovic K; Fradette JJ; Ahmad S; Chen F; Chong Z; Chen K; Creighton CJ; Fu H; Mills GB; Gibbons DL; Scott KL
    Nat Commun; 2018 Jul; 9(1):2732. PubMed ID: 30013058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
    Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
    Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. YTHDF1 Promotes Cyclin B1 Translation through m
    Lou X; Ning J; Liu W; Li K; Qian B; Xu D; Wu Y; Zhang D; Cui W
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.
    Licciulli S; Avila JL; Hanlon L; Troutman S; Cesaroni M; Kota S; Keith B; Simon MC; Puré E; Radtke F; Capobianco AJ; Kissil JL
    Cancer Res; 2013 Oct; 73(19):5974-84. PubMed ID: 23943799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
    Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
    Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer.
    Chakrabarti G
    Radiat Oncol; 2015 Jul; 10():145. PubMed ID: 26173780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
    Gibert J; Clavé S; Hardy-Werbin M; Taus Á; Rocha P; Longarón R; Piquer G; Chaib I; Carcereny E; Morán T; Salido M; Dalmases A; Bellosillo B; Arriola E
    Lung Cancer; 2020 Feb; 140():42-45. PubMed ID: 31862576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The genetics and biology of KRAS in lung cancer.
    Westcott PM; To MD
    Chin J Cancer; 2013 Feb; 32(2):63-70. PubMed ID: 22776234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.